source
- Novartis' Lp(a) drug pelacarsen fails to cut heart attack or stroke risk in phase 3 trialNovartis, in partnership with Ionis, completed the phase 3 Lp(a)Horizon trial of pelacarsen, an antisense oligonucleotide designed to lower lipoprotein(a) levels. The study enrolled more than 8,30…
- Bristol Myers Squibb pauses autoimmune CAR‑T trials after life‑threatening side effectsBristol Myers Squibb announced in early June that it is pausing its CAR‑T therapy trials targeting autoimmune diseases after the trials reported life‑threatening side effects. The company informed…